United Kingdom Veterinary Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Animal Type (Companion Animals, Production Animals), By Product (Biomarker, Kits & Reagents, Biomarker Readers), By Application (Disease Diagnostics, Preclinical Research, and Others), and United Kingdom Veterinary Biomarkers Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Veterinary Biomarkers Market Insights Forecasts to 2035

• The United Kingdom Veterinary Biomarkers Market Size was Estimated at USD 62.45 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 10.30% from 2025 to 2035
• The United Kingdom Veterinary Biomarkers Market Size is Expected to Reach USD 183.60 Million by 2035

According to a research report published by Spherical Insights and Consulting, The United Kingdom Veterinary Biomarkers Market Size is anticipated to reach USD 183.60 Million by 2035, growing at a CAGR of 10.30% from 2025 to 2035. Additional reasons increasing demand for diagnostic veterinary services include government backing, growing use of pet insurance, greater spending on animal healthcare, technological improvements in diagnostics, and strategic expansions by major industry participants.

Market Overview

The United Kingdom veterinary biomarkers market refers to the business focused on the production and application of biomarkers for diagnosing diseases, monitoring animal health, and assessing treatment efficacy in animals. Biomarkers are measurable indicators, such as proteins, genes, or metabolites, that help detect and quantify various physiological and pathological processes in animals. Adoption of biomarkers is required for early diagnosis, monitoring, and treatment evaluation due to the high occurrence of chronic disorders. Adoption of biomarkers improves animal health and well-being by enabling veterinarians to give more precise and timely care. The market for veterinary biomarkers is also expanding more quickly due to the strategic initiatives and higher R&D expenditures of major players, which are spurring innovation in therapeutic and diagnostic solutions. Businesses expend investment on biomarker research in order to increase early disease detection, better treatment results, and diversify their product lines. For instance, the Nu.Q Test, a non-invasive blood test for early canine cancer detection, was introduced in the UK and Ireland in November 2023 by Veterinary Pathology Group (VPG) and VolitionRx. This cutting-edge biomarker-based screening improves diagnosis and treatment results while strengthening preventive care. Through the advancement of early illness detection and the expansion of diagnostic capabilities, its debut fortifies the UK veterinary biomarkers market. So, such major development in the UK boosts the market growth.

Report Coverage

This research report categorizes the market for the United Kingdom veterinary biomarkers market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom veterinary biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom veterinary biomarkers market.

Driving Factors

The market for United Kingdom veterinary biomarkers is influenced by the high demand for biomarker-based assay diagnostic kits in veterinary applications to forecast disease in its early stages is significantly rising due to the rising prevalence of chronic ailments in animals, such as cancer and cardiovascular diseases. The market is expanding as a result of the R&D efforts undertaken by major corporations to improve biomarker portfolios. The market for veterinary biomarkers has enormous potential due to the growing need for portable diagnostic tools, especially for field-visiting clinicians. Additionally, the market is expanding due to increased technology developments in biomarker testing, such as point-of-care and quick diagnostics.

Restraining Factors

The market growth could be limited by some obstacles, for instance, the short shelf life of medicine, the high cost of infrastructure, and the high probability of risk of false positives.

Market Segmentation

The United Kingdom Veterinary Biomarkers Market share is classified into animal type, product, and application.

• The production animals segment held a significant share in 2024 and is expected to grow at a rapid pace during the forecast period.

The United Kingdom veterinary biomarkers market is segmented by animal type into companion animals, and production animals. Among these, the production animals segment held a significant share in 2024 and is expected to grow at a rapid pace during the forecast period. This is due to the expansion as a result of cattle and other livestock. Furthermore, the increasing incidence of severe infectious diseases like tuberculosis in production animals is a significant concern for the development of more diagnostic techniques.

• The biomarker, kits & reagents segment held the largest market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The United Kingdom veterinary biomarkers market is segmented by product into biomarker, kits & reagents, and biomarker readers. Among these, the biomarker, kits & reagents segment held the largest market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. This is due to the abundance of well-known biomarker and test kit brands that have been introduced by prominent market participants. Veterinarians prefer to use biomarker test kits for sensitive and accurate disease diagnosis to track the disease's progression and administer targeted treatments that target the disease's biological indicator. Furthermore, the market's recent expansion has been fueled by increasing awareness of the use of biomarkers in the veterinary industry.

• The preclinical research segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period.

The United Kingdom veterinary biomarkers market is segmented by application into disease diagnostics, preclinical research, and others. Among these, the preclinical research segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period. This is due to the growing field of veterinary biomarker and post-genomic technology research and development. The potential for segment expansion is further increased by the sophisticated tactics used by major players in animal health to find new biomarkers or disease indicators.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom veterinary biomarkers market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Avacta Group PLC
• Dechra Pharmaceuticals Limited
• Dechra Pharmaceuticals Manufacturing
• Animalcare Group plc
• Zoetis UK
• IDEXX Laboratories UK
• Others

Recent Developments:

• In May 2025, Scientists made a breakthrough in diagnosing Johne’s disease using biomarker profiling. A preliminary study by MI: RNA Diagnostics and Scotland’s Rural College (SRUC) showed that MicroRNA (miRNA) profiling, combined with AI-powered predictive modeling, detected Johne’s disease earlier and more reliably than current diagnostic methods. This approach significantly improved animal health, reduced financial strain on farmers, and even lowered greenhouse gas emissions by improving herd management.

• In March 2023, Carus Animal Health announced an investment in advanced UK medical technology through a strategic collaboration with Attomarker, a UK-based medtech company. The partnership aims to develop and commercialize a rapid, portable point-of-care diagnostic device and multiplex assays for veterinary use. This technology, originally used for human healthcare diagnostics, will be adapted to detect a variety of health issues in animals, enabling early detection and improved treatment outcomes.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

arket Segment

This study forecasts revenue at United Kingdom regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom veterinary biomarkers market based on the below-mentioned segments:

United Kingdom Veterinary Biomarkers Market, By Animal Type

• Companion Animals
• Production Animals

United Kingdom Veterinary Biomarkers Market, By Product

• Biomarker
• Kits & Reagents
• Biomarker Readers

United Kingdom Veterinary Biomarkers Market, By Application

• Disease Diagnostics
• Preclinical Research
• Others